Enhanced Gel Ophthalmic Formulations of Pilocarpine and Brimonidine Compounds

The present invention relates to improved gel ophthalmic formulations of pilocarpine and brimonidine compounds, providing enhanced stability, bioavailability, and patient safety for the treatment of ophthalmic conditions such as presbyopia.

The original patent disclosed gel ophthalmic formulations of pilocarpine and brimonidine compounds, but these formulations had limitations, including pH instability, poor bioavailability, and potential eye irritation. The present invention addresses these limitations by introducing novel formulations and manufacturing processes that enhance the overall performance and safety of the ophthalmic compositions.

The new inventive concept comprises a system for treating an ocular condition, featuring a gel composition containing pilocarpine and brimonidine compounds, formulated to maintain a consistent pH level between 5.5 and 6.5, thereby enhancing the stability of the active pharmaceutical ingredients. Additionally, the composition incorporates a solubility enhancer to increase the rate of absorption of the active pharmaceutical ingredients, providing improved bioavailability. The formulation is designed to provide a rapid onset of action and a prolonged duration of effect, improving patient compliance. Furthermore, the manufacturing process is optimized to minimize the risk of eye irritation and improve the clarity and stability of the final product.

The new claims introduce novel and non-obvious improvements to the original patent, including the use of pH-maintaining excipients, solubility enhancers, and optimized manufacturing processes. These advancements provide a significant enhancement in the performance and safety of the ophthalmic compositions, making them more effective and user-friendly.

Alternative embodiments of the inventive concept may include variations in the type and concentration of pilocarpine and brimonidine compounds, different solubility enhancers, and alternative manufacturing processes. Additionally, the inventive concept could be adapted for use in other ophthalmic conditions, such as glaucoma or dry eye syndrome.

The enhanced gel ophthalmic formulations of pilocarpine and brimonidine compounds have significant commercial potential in the ophthalmic pharmaceutical industry, particularly in the treatment of presbyopia and other ophthalmic conditions. The improved performance, safety, and patient compliance of these formulations make them an attractive option for patients and healthcare providers, potentially capturing a significant market share.